Docetaxel, Cisplatin, 5-FU Combination Chemotherapy as a First-Line Treatment in Patients with Advanced Gastric Cancer.
- Author:
Bu Kyung KIM
1
;
Moo In PARK
;
Seun Ja PARK
;
Kyu Jong KIM
;
Won MOON
;
Su Hyeon JEONG
;
Hye Soo KIM
;
Sung Jin NAM
Author Information
1. Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea. mipark@kosinmed.or.kr
- Publication Type:Original Article
- Keywords:
Docetaxel;
Cisplatin;
5-FU;
Gastric cancer
- MeSH:
Anemia;
Cisplatin;
Drug Therapy, Combination;
Fever;
Fluorouracil;
Humans;
Leukopenia;
National Cancer Institute (U.S.);
Neutropenia;
Stomach Neoplasms;
Taxoids;
Thrombocytopenia
- From:Korean Journal of Medicine
2011;80(6):680-686
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: This study investigated the efficacy and safety of docetaxel/cisplatin/5-fluorouracil (DCF) combination chemotherapy as a first-line treatment in patients with advanced gastric cancer. METHODS: The study enrolled 48 patients diagnosed with unresectable pathologically proven gastric cancer who received DCF combination chemotherapy between April 2006 and August 2009. The dose administered was docetaxel 75 mg/m2 for 1 h and cisplatin 75 mg/m2 for 90 min on day 2, and 5-FU 750 mg/m2 for 24 h on days 1-5, every 3 weeks. The response was assessed every three cycles. The toxicity was evaluated for every chemotherapy course according to the National Cancer Institute (NCI) toxicity criteria ver. 2.0. RESULTS: The median age of the patients was 58 years (range 31-78 years). The median overall survival was 11.5 months (2.3-28.2 months) and the median time to progression was 5.5 months (0.3-18.9 months). No complete remission occurred. Of the patients, 56% achieved a partial response, 21% stable disease, and 10% progressive disease. The overall response rate was 56%. During a total 292 cycles, anemia worse than NCI toxicity grade 3 occurred in 2%, leukopenia in 33.1%, neutropenia in 67.1%, and thrombocytopenia in 4.4%. Neutropenic fever occurred in 33 cycles (11.3%), dose reduction due to side effects in 165 cycles (56.5%), and a regimen change due to side effect in five cycles (1.7%). CONCLUSIONS: Combination chemotherapy with docetaxel, cisplatin, and 5-FU is efficacious, but has relatively high toxicity. A DCF protocol that maximizes its efficiency, while minimizing toxicity, would be more useful as a first-line treatment in patients with advanced gastric cancer.
